Oncology

Latest News

Highlights From ACCC Fall 2024
ICYMI: Highlights From ACCC Fall 2024

January 1st 2025

Top content from the Association of Cancer Care Centers (ACCC) fall conference included topics on patient participation, new cancer care programs, prior authorization processing, and more.

Top 5 Most-Read Oncology Articles of 2024
Top 5 Most-Read Oncology Content of 2024

December 25th 2024

Most Popular Articles of 2024 in Evidence-Based Oncology
Most Popular Articles of 2024 in Evidence-Based Oncology

December 23rd 2024

Highlights From ASCO 2024
ICYMI: Highlights From ASCO 2024

December 21st 2024

chemotherapy | Image credit: Penn Medicine
The High Cost of Shortages of Low-Cost Chemotherapy

December 19th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

This Week in Managed Care: October 14, 2016
October 14th 2016

This Week in Managed Care: October 14, 2016

This week, the top stories in managed care included HHS releasing the final rule for the Medicare Access and CHIP Reauthorization Act, a commentary on the downside of drug coupons, and the World Health Organization called on countries to enact a soda tax.
Site Logo
October 12th 2016

Radiomics to Predict Response to Antiangiogenic Therapy in Glioblastoma

Surabhi Dangi-Garimella, PhD
Radiomic combines imaging and computational technologies and can identify patients with recurrent glioblastoma who may benefit from using angiogenesis inhibitors.
Site Logo
October 12th 2016

Compassionate Use: FDA Is on Board, but Are Drug Manufacturers?

Surabhi Dangi-Garimella, PhD
A survey by Avalere Health found that only 19% of drug makers publicly post policies about their compassionate use programs.
Site Logo
October 12th 2016

What We're Reading: Limiting Use of Fentanyl, the Drug Fueling the Opioid Epidemic

AJMC Staff
What we're reading, October 12, 2016: a US senator calls for a limit to prescription fentanyl; healthcare costs aren't skyrocketing, despite claims; IBM's Watson will identify cancer treatment and clinical trials for IBM employees.
Site Logo
October 11th 2016

Reducing the Cost of Breast Cancer Treatment by $1 Billion

Surabhi Dangi-Garimella, PhD
A retrospective study in breast cancer patients suggests that patients can lower their out-of-pocket costs by speaking with their oncologist about alternate treatments that may be equally effective and understanding the drug coverage policy of their insurance plan.
Site Logo
October 11th 2016

Why You Should Attend Patient-Centered Oncology Care in Baltimore

Innovation in oncology treatments has reduced the mortality rate for cancer, but it comes at a price. At the 5th Annual Patient-Centered Oncology Care, experts will discuss cost-sharing models, as well as updates in cancer care treatment, such as precision medicine and immuno-oncology.
Site Logo
October 10th 2016

COST: A New Tool to Measure Financial Toxicity as a PRO

Surabhi Dangi-Garimella, PhD
Researchers at the University of Chicago have developed a clinically relevant patient-centered tool that can measure a patient’s risk for financial stress.
Site Logo
October 10th 2016

Estimating the Social Value of G-CSF Therapies in the United States

Jacqueline Vanderpuye-Orgle, PhD Alison Sexton Ward, PhD Caroline Huber, MPH Chelsey Kamson, BS Anupam B. Jena, MD, PhD
Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.
Site Logo
October 10th 2016

Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC

Surabhi Dangi-Garimella, PhD
While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1—expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.
Site Logo
October 7th 2016

Tamoxifen and AI Can Reduce Long-Term Risk of Contralateral Breast Cancer

Surabhi Dangi-Garimella, PhD
A retrospective analysis has found that longer term adjuvant treatment with tamoxifen significantly decreases the risk of contralateral breast cancer.
This Week in Managed Care: October 7, 2016
October 7th 2016

This Week in Managed Care: October 7, 2016

This week, the top managed care stories included conference coverage from the Academy of Managed Care Pharmacy's 2016 Nexus, Bill Clinton courted controversy when discussing the Affordable Care Act, and research finds fear of a job loss can increase the risk of diabetes.
Site Logo
October 7th 2016

Will HHS Have the Assurance of a Patient Identifier?

Surabhi Dangi-Garimella, PhD
HHS has been banned from using a patient identifier but several organizations, including national payers, providers, and prescription drug networks, want this reversed.
Site Logo
October 6th 2016

State-Level Insurance Reform Improved Access for Patients With CRC in Massachusetts

Surabhi Dangi-Garimella, PhD
A study published in the Journal of Clinical Oncology found an increased rate of resection and a reduction in the probability of emergent resection for colorectal cancer (CRC) as a result of insurance expansion in Massachusetts.
Site Logo
October 5th 2016

COA Report Accentuates Economic Strain on Community Practices

Surabhi Dangi-Garimella, PhD
According to the 2016 Community Oncology Practice Impact Report, about 15 community practices in the United States have either closed or were acquired, each month since 2008.
Site Logo
October 5th 2016

Following Nivolumab, NICE Rejects Pembrolizumab for Use in Patients With NSCLC

Surabhi Dangi-Garimella, PhD
A draft guidance issued by the National Institute for Health and Care Excellence (NICE) rejected use of Merck's programmed death-1 inhibitor pembrolizumab (Keytruda) in patients diagnosed with non-small cell lung cancer (NSCLC).
Site Logo
October 4th 2016

The Power of an Immuno-oncology Collaborative Care Team

Surabhi Dangi-Garimella, PhD
At the Institute for Clinical Immuno-Oncology National Conference, a panel of care providers presented institutional experiences with immunotherapy, and how a collaborative care approach helped the process.
Site Logo
October 4th 2016

PanCAN's Precision Medicine Trial Designed for Collaboration and Personalized Care

Surabhi Dangi-Garimella, PhD
Precision Promise, the Pancreatic Cancer Action Network (PanCAN)'s precision medicine trial, seeks to transform outcomes for pancreatic cancer patients with the goal set to double survival by 2020.
Site Logo
October 4th 2016

Specialty Pharmaceutical Pipeline: Increased Competition, Biosimilar Uncertainty

Laura Joszt, MA
Perennial favorite, Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapeutics at Express Scripts, opened the Academy of Managed Care Pharmacy 2016 Nexus, October 3, 2016, in National Harbor, Maryland, with a discussion of specialty pharmaceutical drugs in the pipeline.
Daniel J. Klein Highlights the Financial Assistance PAN Provides Patients
October 4th 2016

Daniel J. Klein Highlights the Financial Assistance PAN Provides Patients

The funds that the Patient Access Network (PAN) Foundation provides to patients are often used to help with the cost of medications, and there has been a large increase in the number of patients looking for assistance for the cost of cancer treatments, explained Daniel J. Klein, president and CEO of the PAN Foundation.
Site Logo
October 3rd 2016

Knowledge Is Power for Cancer Patients, British Study Says

Christina Mattina
A study suggests that regions of England where patients show less awareness of cancer symptoms tend to have lower cancer survival rates, particularly in lower-income areas. The research, published in the British Journal of Cancer also examined whether barriers to care can affect the likelihood of surviving different cancers.
Site Logo
October 3rd 2016

Remarkable Outcomes With Cancer Immunotherapy, but Clinical Adoption Remains Challenging

Surabhi Dangi-Garimella, PhD
The cancer community has seen tremendous progress in the field of immunotherapy. However, educating patients and care providers across healthcare on this new tool remains a significant challenge.
This Week in Managed Care: October 1, 2016
October 1st 2016

This Week in Managed Care: October 1, 2016

This week, the top stories in managed care included 2 reports on the fight against addiction, researchers have learned more about the effects of healthy living on avoiding cancers, and a study finds fitness trackers do not help people lose more weight.
Site Logo
September 30th 2016

Sentinel Lymph Node Biopsy: Part of Melanoma Treatment's Exciting Future

Timothy M. Johnson, MD, spoke enthusiastically about the possibilities of sentinel lymph node biopsy in his lecture at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria. His presentation, called “Melanoma Sentinel Node Biopsy: Past, Present and Future in the New Era of Systemic Therapies,” covered guidelines for the procedure as well as new possibilities for melanoma patients.
Site Logo
September 30th 2016

ICER Recommends Significant Discount on WAC for Checkpoint Inhibitors in NSCLC

Surabhi Dangi-Garimella, PhD
Based on ICER’s evaluation, a significant reduction in the wholesale acquisition cost (WAC) of approved checkpoint inhibitors would be necessary to achieve a pre-determined value-based price benchmark.
Site Logo
September 30th 2016

New Anticancer Drugs Associated With Big Increases in Costs, but Also Life Expectancy

Jackie Syrop
While there have been large increases in the cost of new cancer treatments for patients with metastatic breast, lung, or kidney cancer, or chronic myeloid leukemia, researchers found that there were also large gains in life expectancy.
Dr Mario E. Lacouture on Maintaining Quality of Life While Treating Melanomas
September 30th 2016

Dr Mario E. Lacouture on Maintaining Quality of Life While Treating Melanomas

Patients with melanoma have more promising options than ever with the advent of targeted therapies and immunotherapies, said Mario Lacouture, MD, director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center. His research aims to provide patients the best possible quality of life while taking these treatments, which can often have adverse effects.
Site Logo
September 29th 2016

Preventive Oophorectomy Contraindicated in Women With an Average Risk of Ovarian Cancer

Surabhi Dangi-Garimella, PhD
Researchers at the Mayo Clinic are recommending that premenopausal women with a low risk of ovarian cancer should be spared unnecessary comorbidities associated with bilateral oophorectomy.
Site Logo
September 29th 2016

Need to Revisit Cervical Cancer Screening Guidelines: JAMA Oncology Study

Surabhi Dangi-Garimella, PhD
A new study has found that after adjusting for changes in screening, there was a decrease in incidence of all grades of cervical intraepithelial neoplasia (CIN) for women 15- to 19-years old, and CIN grade 2 in women 20- to 24-years old.
Site Logo
September 28th 2016

USPSTF Recommendation Did Not Impact PSA Testing Referrals, Study Finds

Surabhi Dangi-Garimella, PhD
A study published in the journal Cancer has discovered that a 2012 recommendation for prostate cancer screening did not change physician behavior.
Dr Ally-Khan Somani: Mohs Surgery Is a Gold Standard
September 28th 2016

Dr Ally-Khan Somani: Mohs Surgery Is a Gold Standard

Mohs surgery is generally the gold standard for rare and more aggressive tumors because the surgeon can ensure the roots of the tumor are gone, but the technique keeps the hole small, said Ally-Khan B. Somani, MD, PhD, at the 25th European Academy of Dermatology and Venereology Congress.
<1
...
868788899091929394
...
181>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo